ASH 2023 | Venetoclax & dose-reduced chemotherapy for the treatment of older adults with B-ALL and T-ALL
Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses a Phase Ib/II trial (NCT03319901) investigating venetoclax & dose-reduced chemotherapy as an alternative to conventional chemotherapy, which is associated with significant toxicity in older adults with B-cell or T-cell acute lymphoblastic leukemia (ALL). The trial found this drug combination to be well-tolerated, with a measurable residual disease (MRD) negativity rate of 90%. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Novartis, Pfizer, Jazz
Research Funding: Novartis, AbbVie
